financetom
Business
financetom
/
Business
/
Structure Therapeutics Closes $547.4 Million Offering
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Structure Therapeutics Closes $547.4 Million Offering
Jun 7, 2024 1:54 PM

04:24 PM EDT, 06/07/2024 (MT Newswires) -- Structure Therapeutics ( GPCR ) said late Friday it closed its upsized underwritten public offering of about 10.4 million American depositary shares, including the full exercise of the underwriters' option to buy up to about 1.4 million additional ADSs, at $52.50 per ADS, for gross proceeds of about $547.4 million.

All of the ADSs were offered by Structure, the company said.

Price: 52.83, Change: -0.24, Percent Change: -0.45

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Trulieve Cannabis Q4 Earnings: Revenue Beat, EPS Beat, 10 Dispensaries Added, Management Changes And More
Trulieve Cannabis Q4 Earnings: Revenue Beat, EPS Beat, 10 Dispensaries Added, Management Changes And More
Feb 27, 2025
Trulieve Cannabis Corp ( TCNNF ) reported financial results for the fourth quarter before the market open on Thursday. Here’s a rundown of the report. Q4 Earnings: Trulieve reported fourth-quarter revenue of $301 million, beating analyst estimates of $292.64 million, according to Benzinga Pro. The cannabis company reported fourth-quarter adjusted earnings of 2 cents per share, beating estimates for a...
Chubb to Recommend Dividend Increase
Chubb to Recommend Dividend Increase
Feb 27, 2025
10:49 AM EST, 02/27/2025 (MT Newswires) -- Chubb ( CB ) said Thursday its board will recommend to increase its quarterly dividend at its 2025 annual general meeting. Chubb ( CB ) said the proposal calls for a $3.88 annual per share dividend, payable in four quarterly installments of $0.97 per share, against the current quarterly dividend of $0.91 per...
BioRestorative Therapies Says FDA Clears BRTX-100 Trial in Chronic Cervical Discogenic Pain
BioRestorative Therapies Says FDA Clears BRTX-100 Trial in Chronic Cervical Discogenic Pain
Feb 27, 2025
10:48 AM EST, 02/27/2025 (MT Newswires) -- BioRestorative Therapies ( BRTX ) said Thursday that the US Food and Drug Administration has cleared its investigational new drug application for BRTX-100 to potentially treat chronic cervical discogenic pain. BioRestorative Chief Executive Officer Lance Alstodt said the company is planning to carry out a phase 2 study to evaluate BRTX-100's safety and...
--Turkcell Stock Trading Halted, Pending Material News Release
--Turkcell Stock Trading Halted, Pending Material News Release
Feb 27, 2025
10:45 AM EST, 02/27/2025 (MT Newswires) -- Price: 7.38, Change: +0.08, Percent Change: +1.10 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved